DOV Confident Of Bicifadine "Residual Value" For Pain After Phase III Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
DOV's analysis of a failed Phase III trial of its non-opioid analgesic bicifadine for chronic low back pain could be used to modify future and ongoing studies for the indication, according to the company